Menu Close

New York State Common Retirement Fund Increases Stock Holdings in Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)

New York State Common Retirement Fund increased its holdings in shares of Theseus Pharmaceuticals, Inc. (NASDAQ:THRXGet Rating) by 475.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,495 shares of the company’s stock after buying an additional 7,844 shares during the period. New York State Common Retirement Fund’s holdings in Theseus Pharmaceuticals were worth $109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Boxer Capital LLC acquired a new position in Theseus Pharmaceuticals in the 4th quarter valued at $11,311,000. Adage Capital Partners GP L.L.C. acquired a new position in Theseus Pharmaceuticals in the 4th quarter valued at $9,657,000. Omega Fund Management LLC acquired a new position in Theseus Pharmaceuticals in the 4th quarter valued at $9,022,000. Nextech Invest AG acquired a new position in Theseus Pharmaceuticals in the 4th quarter valued at $7,751,000. Finally, Foresite Capital Opportunity Management V LLC acquired a new position in Theseus Pharmaceuticals in the 4th quarter valued at $5,945,000. Hedge funds and other institutional investors own 90.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright began coverage on Theseus Pharmaceuticals in a research note on Thursday, June 30th. They issued a “buy” rating and a $22.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $24.40.

Theseus Pharmaceuticals Stock Down 0.8 %

Shares of THRX opened at $7.53 on Tuesday. Theseus Pharmaceuticals, Inc. has a 52-week low of $4.86 and a 52-week high of $24.54. The company has a market capitalization of $291.51 million and a PE ratio of -1.26. The stock has a fifty day simple moving average of $6.78 and a two-hundred day simple moving average of $8.85.

Theseus Pharmaceuticals Company Profile

(Get Rating)

Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.

Featured Articles

Receive News & Ratings for Theseus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.